Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors

The COVID-19 outbreak has rapidly spread on a global scale, affecting the economy and public health systems throughout the world. In recent years, peptide-based therapeutics have been widely studied and developed to treat infectious diseases, including viral infections. Herein, the antiviral effects...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecules (Basel, Switzerland) Switzerland), 2021-08, Vol.26 (16), p.4896, Article 4896
Hauptverfasser: Freire, Marjorie C. L. C., Noske, Gabriela D., Bitencourt, Natalia V., Sanches, Paulo R. S., Santos-Filho, Norival A., Gawriljuk, Victor O., de Souza, Eduardo P., Nogueira, Victor H. R., de Godoy, Mariana O., Nakamura, Aline M., Fernandes, Rafaela S., Godoy, Andre S., Juliano, Maria A., Peres, Bianca M., Barbosa, Cecilia G., Moraes, Carolina B., Freitas-Junior, Lucio H. G., Cilli, Eduardo M., Guido, Rafael V. C., Oliva, Glaucius
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The COVID-19 outbreak has rapidly spread on a global scale, affecting the economy and public health systems throughout the world. In recent years, peptide-based therapeutics have been widely studied and developed to treat infectious diseases, including viral infections. Herein, the antiviral effects of the lysine linked dimer des-Cys(11), Lys(12),Lys(13)-(pBthTX-I)(2)K ((pBthTX-I)(2)K)) and derivatives against SARS-CoV-2 are reported. The lead peptide (pBthTX-I)(2)K and derivatives showed attractive inhibitory activities against SARS-CoV-2 (EC50 = 28-65 mu M) and mostly low cytotoxic effect (CC50 > 100 mu M). To shed light on the mechanism of action underlying the peptides' antiviral activity, the Main Protease (M-pro) and Papain-Like protease (PLpro) inhibitory activities of the peptides were assessed. The synthetic peptides showed PLpro inhibition potencies (IC(50)s = 1.0-3.5 mu M) and binding affinities (K-d = 0.9-7 mu M) at the low micromolar range but poor inhibitory activity against M-pro (IC50 > 10 mu M). The modeled binding mode of a representative peptide of the series indicated that the compound blocked the entry of the PLpro substrate toward the protease catalytic cleft. Our findings indicated that non-toxic dimeric peptides derived from the Bothropstoxin-I have attractive cellular and enzymatic inhibitory activities, thereby suggesting that they are promising prototypes for the discovery and development of new drugs against SARS-CoV-2 infection.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules26164896